Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biotech Exelixis
So what: The drug in question, cabozantinib, is an experimental prostate cancer drug, and the company plans on measuring its effectiveness by pain reduction in the trial. Exelixis has decided to proceed with the study since it is in the company's best interest, despite lacking regulators' blessings.
Now what: Exelixis is looking to initiate the trial by year's end, and a different trial to measure overall survival in the first half of 2012. The company indicated that leading investigators and consultants advised it to proceed, since it would be in the best interests of patients and Exelixis to initiate the trial as soon as possible. It's a risky move to proceed without getting regulators to sign off on the trial, but biotech investors should be no strangers to risk.
Interested in more info on Exelixis? Add it to your watchlist by clicking here.
Fool contributor Evan Niu holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Exelixis. Motley Fool newsletter services have recommended buying shares of Exelixis. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
4 Reasons Exelixis, Inc. More Than Doubled in 2017
A 104% gain last year wouldn't have been possible without lead drug Cabometyx.
The Secret Sauce Behind Exelixis, Inc.'s 12% Move Higher in December
Hint: It has everything to do with lead drug Cabometyx.
Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors
This already well-performing biotech stock could have a lot more climbing to do.